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Abstract
Recent human trials of treatments for Alzheimer’s disease (AD) have been largely unsuccessful, raising the idea that
treatment may need to be started earlier in the disease, well before cognitive symptoms appear. An early marker of AD
pathology is therefore needed and it is debated as to whether amyloid-b (Ab) plaque load may serve this purpose. We
investigated this in the hAPP-J20 AD mouse model by studying disease pathology at 6, 12, 24 and 36 weeks. Using robust
stereological methods, we found there is no neuron loss in the hippocampal CA3 region at any age. However loss of
neurons from the hippocampal CA1 region begins as early as 12 weeks of age. The extent of neuron loss increases with age,
correlating with the number of activated microglia. Gliosis was also present, but plateaued during aging. Increased
hyperactivity and spatial memory deficits occurred at 16 and 24 weeks. Meanwhile, the appearance of plaques and
oligomeric Ab were essentially the last pathological changes, with significant changes only observed at 36 weeks of age.
This is surprising given that the hAPP-J20 AD mouse model is engineered to over-expresses Ab. Our data raises the
possibility that plaque load may not be the best marker for early AD and suggests that activated microglia could be a
valuable marker to track disease progression.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized symptomatically by impaired memory, alterations
to personality and decreased visual-spatial skills. Pathologically,
AD is characterized by a loss of neurons, central inflammation,
amyloid-b (Ab) aggregation into plaques and by the formation of
neurofibrillary tangles (NFTs) consisting of hyperphosphorylated
tau [1]. Of these hallmarks, plaque load has historically been
regarded as the definitive diagnosis of AD at autopsy of a person
who had dementia [2].
Plaques result from the cleavage of the Ab precursor protein
(APP) by b- and c-secretases into 39–43 amino acid Ab peptides
within the cerebral cortex, hippocampus and amygdala [3,4]. In
the normal state, APP is cleaved to produce a fragment of 40
amino acids in length termed Ab40. However, in AD, cleavage
often results in an overproduction of the more fibrillogenic form,
Ab42, which can form neuritic plaques [5]. Since plaque load has
been regarded as both a hallmark and cause of AD, numerous
recent drug trials have focused on reducing fibrillogenic Ab.
Unfortunately, to date these clinical trials have largely failed,
raising the notion that the treatments are being delivered too late
in the disease progression, and/or that reducing Ab load may not
be the best target for preventing AD progression.
Plaque load has long been considered to be the major hallmark
and therapeutic target for AD, and as such it is now being
extensively investigated as an early prognostic marker of AD.
Consequently, the first FDA-approved Ab imaging ligand
(AmyvidTM), which detects neuritic plaques, has recently been
released. However, there is still debate as to the clinical relevance
of neuritic plaques as the correlation between plaque deposition
and cognitive status is not clear [6,7,8]. Furthermore, plaques can
be detected in people without cognitive deficits indicating that
plaque load may not be the most precise biomarker for AD [9,10].
While the pathognomonic hallmarks of AD include plaques, AD
is also associated with NFTs, neuronal loss and increased
neuroinflammation [11]. Neuronal loss is usually prominent in
the hippocampus, especially the CA1 region, and is further
detected throughout the cerebral cortex, increasing with disease
progression [12]. In addition, postmortem studies have also
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demonstrated significant neuroinflammatory changes in brain
tissue from AD patients [3]. Microglia, the brain’s local
macrophage, and astrocytes are known to produce pro-inflamma-
tory cytokines such as tumor necrosis factor-alpha (TNF-a) and
interleukin-6 (IL-6) when activated [13,14,15]. These, and other,
cytokines have been implicated in neurodegeneration and plaque
formation [11,16]. Despite an understanding that neuroinflamma-
tion and neuronal loss contribute to disease progression, the timing
of these events is undetermined. It is apparent from the current
debate that a full understanding of the time course of AD
pathology as it relates to symptoms is required, both to allow
accurate diagnosis and to potentially identify events early in
disease that could be targeted for treatment.
In this study we therefore aimed to determine the timing of
common pathological markers of AD including Ab oligomer
formation, Ab plaque load, neuronal loss, and neuroinflammation.
These classical hallmarks have previously been reported in mouse
models of AD that overexpress APP [17,18,19,20,21]. In
particular, the J20 mouse model, generated by Mucke et al.
(2000) is of interest as it develops early plaque formation from
several months of age, has severe synaptic dysfunction, and is
susceptible to seizure activity [22,23,24,25,26,27]. This line
expresses human APP (hAPP) bearing two mutations; the Swedish
(K595N) and Indiana (M596L) mutations. However, the timing of
pathological events has not been well characterized in the hAPP-
J20 mouse model.
In order to address the timing of pathological events, we
adopted a highly accurate and unbiased stereological counting
method to detect age-dependent changes in the number of
neurons, astrocytes, and microglia in the hippocampus of hAPP-
J20 mice and their wild-type (WT) littermates. Tau hyperpho-
sphorylation does not occur in these mice and was therefore not
investigated in this study [28]. By accurately quantifying cell
numbers, we have identified that neuronal cell loss and
inflammatory changes occur well in advance of the formation of
Ab plaques. Current pharmacological trials are based on reducing
plaque load and significant worldwide effort is being made to
identify methods of imaging plaques as a marker of disease
progression [29,30]. Our findings therefore have important
therapeutic implications because they suggest that plaque load
may be among the last events, occurring late in the disease process,
after cell loss and inflammatory elevation.
Methods
Mice
Male hemizygous transgenic (hAPP-J20) and non-transgenic
mice (WT) were from the J20 line, which express h-APP
containing both the Swedish and Indiana mutations, under a
PDGF-b chain promoter [24]. Mice were housed at a maximum
five mice per cage, until the study began, at which time mice were
housed individually. Mice were kept on a 12 h light/dark cycle
(lights on at 7:00 am). Food and water were available ad libitum
until dietary restrictions began. All animal experiments were
performed with the approval of the Garvan Institute and St.
Vincent’s Hospital Animal Ethics Committee, in accordance with
National Health and Medical Research Council animal experi-
mentation guidelines and the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (2004).
Immunofluorescence
Mice were anesthetized with ketamine (8.7 mg/mL) and
xylazine (2 mg/mL) and transcardially perfused with 4% para-
formaldehyde (PFA). Brains were harvested and postfixed in 4%
PFA for 6 h before being transferred to 30% sucrose. Brains were
sectioned coronally (40 mm) with a cryostat. Free-floating sections
were used. For the detection of Ab oligomers, sections were
washed three times in phosphate buffered saline (PBS) and
incubated for 1 h at room temperature in 15% Fetal Bovine
Serum (FBS) +0.1% Triton-X 100 (TX-100) blocking solution.
Sections were incubated overnight at 4uC in the anti-Ab oligomer
antibody, A11 (1:100, Millipore). Sections were washed three times
in PBS and incubated in Alexa Fluor 594 Goat anti-rabbit IgG
(1:250, Invitrogen) for 3 h at room temperature. Sections were
mounted and cover slipped with Kaisers glycerol gelatin solution
(Merck). Slides were imaged using a Zeiss Axioplan upright
fluorescence microscope with Zeiss Axiocam MRm digital camera.
Digital images were captured using Axiovision V 4.8.1.0 software.
Immunohistochemistry
Endogenous peroxidases were quenched using 3% H202 and
were subjected to blocking with 3% Bovine Serum Albumin (BSA)
+0.25% TX-100 in PBS. Sections were incubated in the following
primary antibodies: mouse anti-NeuN (1:500; Chemicon), rat anti-
CD68 (1:100; AbD Serotec), and rabbit anti-GFAP (1:300; Dako)
for 72 h at 4uC followed by biotin-labeled secondary antibodies,
HRP-labeled avidin-biotin complex and 3,39-Diaminobenzidine
(DAB). Sections stained for CD68 and GFAP were counterstained
with mouse anti-NeuN that was detected with Nova-Red to
outline the region of interest. Sections were mounted and cover
slipped with Kaisers glycerol gelatin solution (Merck). For
detection of total Ab, sections were incubated in a biotinylated
6E10 antibody (1:1000, Covance) for 24 h at 4uC and subjected to
HRP-labeled avidin-biotin complex and DAB.
Quantification of Total Ab
Quantification of the 6E10 staining was performed using the
Image-Pro Plus v.6.0 image analysis system to analyze the percent
area occupied by positive staining. Images from the hippocampal
region subfield at the antero-posterior (AP) positions from bregma
between 21.34 mm and 22.3 mm were collected at 106magni-
fication (five sections per animal). Captured images were imported
into Image-Pro Plus and an intensity threshold level was set to
allow for the discrimination between 6E10 positive staining and
background labeling. The percentage of positive staining was
calculated as the Ab deposition load.
Ab Plaque Quantification
Thioflavine S staining was used to determine fibrillar Ab plaque
deposition. Sections were slide mounted and allowed to dry, prior
to being washed with distilled water and treated with 70% and
80% EtOH for five minutes. Slides were incubated for 15 minutes
with 1% thioflavine S in 80% ethanol. Plaque counts were
conducted in the hippocampal region subfield from five sections
per animal at the antero-posterior (AP) positions from bregma
between 21.34 mm and 22.3 mm. All plaque counts were
conducted manually and were blind to genotype and age. Slides
were imaged using a Zeiss Axioplan upright fluorescence
microscope with Zeiss Axiocam MRm digital camera. Digital
images were captured using Axiovision V 4.8.1.0 software.
Dot Blot
Mice were cervically dislocated and the hippocampus was
rapidly dissected from the brain of hAPP-J20 and WT mice and
frozen at 280uC until use. Tissue was homogenized in RIPA
buffer supplemented with protease inhibitors. Protein concentra-
tions of the supernatant were measured using a Bradford assay and
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samples were adjusted to the same concentrations with SDS
buffer. 20 mg of extract was applied to a nitrocellulose membrane
and air-dried. Membranes were incubated in a 10% solution of
nonfat dry milk for 1 h at room temperature and overnight at 4uC
in A11 (1:1000, Millipore). Membranes were then washed, before
being incubated in HRP-conjugated secondary and visualized by
ECL. Films were scanned and Ab oligomer levels were quantified
using Image J Software. For quantification of dot blots, the raw
values obtained from hAPP-J20 mice were adjusted with the values
obtained from the WT mice.
Ab ELISA
Hippocampi from hAPP-J20 mice were weighed and homog-
enized in 5vol/wt of Tris-buffered saline (TBS) (Tris-HCL 50 mM
pH 7.6; NaCl 150 mM; EDTA 2 mM) containing a cocktail of
protease inhibitors. Samples were then suspended in 2% SDS
containing protease inhibitors and centrifuged at 100,000 g for 60
minutes at 4uC. The supernatant was collected for the soluble Ab
ELISA. The Ab levels were determined by using the commercially
available BetaMark Total Beta-Amyloid Chemiluminescent
ELISA Kit (Covance).
Stereology
Quantification of cell population estimates were made using
Stereo Investigator 7 (Microbrightfield) as previously described
[31,32]. Estimates were conducted on the dorsal hippocampus at
the antero-posterior (AP) positions from bregma between
21.34 mm and 22.3 mm. For neuronal population estimates, a
minimum 20 sampling sites were sampled per section on a grid size
of 84 mm660 mm and a counting frame size of 30 mm630 mm.
For GFAP-positive astrocyte population estimates, a minimum of
30 sampling sites per section on a grid size of 68 mm668 mm and a
counting frame size of 30 mm630 mm. For CD68-positive
microglial population estimates, a minimum of 40 sampling sites
were sampled per section on a grid site of 114 mm668 mm and a
counting frame size of 65 mm665 mm. For all cell population
estimates, a guard zone of 5 mm and a dissector height of 10 mm
were used. Each marker was assessed at one in every sixth section,
with a total of five sections being sampled. The regions sampled
included the CA3 and CA1 regions of the hippocampus for
neuronal and astrocyte populations. Microglia populations were
sampled within the borders of the CA1, CA3 and dentate gyrus
(DG) regions of the hippocampus. All stereological cell counts were
performed blind to genotype and age.
Behavior
Open field test. The open field test arena (40640 cm) was
situated in a large box with clear plexiglass walls, no ceiling, and a
white floor. Each chamber was set inside a larger sound-
attenuating cubicle with lights illuminating the arena and a fan
to eliminate background noise. Mice were placed into the center of
the arena and allowed to explore the test box for 10 minutes, while
a computer software program (Activity Monitor; Med Associates)
recorded activity via photobeam detection inside the testing
chambers as a measure of general activity levels. The total distance
traveled over the course of the 10 minutes was recorded. The
arena was cleaned with 70% ethanol (EtOH) between each mouse.
Elevated plus test. The elevated plus-maze consists of four
arms (77610 cm) elevated (70 cm) above the floor. Two of the
arms contained 15 cm-high walls (enclosed arms) and the other
two consisted of no walls (open arms). Each mouse was placed in
the middle of the maze facing a closed arm and allowed to explore
the maze for five minutes. A video camera recorded the mouse
and a computer software program (Limelight; Med Associates) was
used to measure the time spent in the open arms, as an indication
of anxiety-like behavior. The maze was cleaned with 70% EtOH
between each mouse.
Radial arm maze. The radial arm maze (RAM) consists of
eight arms (6569 cm), extending radially from a central arena
(35 cm diameter), elevated (90 cm) above the ground. Each arm
and the central arena were made of plexiglass, with enclosing walls
made of clear plexiglass. The RAM was cleaned with 70% EtOH
between each mouse.
Mice were individually housed and restricted to 85% of their
original body weight for one week prior to the commencement of
RAM testing. On the first and second day, mice were habituated
to the maze by being placed into the central arena, with each of
the eight arms baited with sweetened condensed milk, and were
allowed to explore the maze for 10 minutes. Starting on the third
day, and continuing for 24 days twice a day, mice were subjected
to a reference memory task, where the same three of the eight
arms were baited with sweetened condensed milk. The training
trial continued until all three baits were retrieved or until five
minutes had elapsed. After a 14-day rest period mice were
presented to a retention trial where the same arms were baited
with sweetened condensed milk.
An investigator recorded measures, with the number of
successful entries into the baited arms (where the sweetened
condensed milk was consumed) being divided by the total number
of entries made. Data is presented as ‘‘Session’’, consisting of two
days (a total of four trials).
Fear Conditioning
Training and testing took place in two identical cube-shaped
fear-conditioning chambers (32627626 cm; Med Associates Inc.)
that had a clear plexiglass door, ceiling and rear wall and grey
aluminum side walls. Each chamber had a removable grid floor,
which consisted of 36 parallel rods spaced 8 mm apart. Positioned
under the grid was a removable grey aluminum tray for collection
of waste. The rods were connected to a shock generating and
scrambling system, which delivered a current to elicit a foot shock.
This system was connected to and controlled by computer
software (FreezeFrame2, Actimetrics). A video camera, which
was positioned in front of the chambers, recorded the behavior of
the mice during training and testing. The fear-conditioning
chamber was cleaned with 70% EtOH and the waste tray was
scented with aniseed essence between each mouse.
On the conditioning day, mice were placed into a fear-
conditioning chamber in which the environment (context) was
controlled. Mice were allowed to explore the context freely for 1
minute prior to receiving a single moderate footshock (0.5 mA, 2s).
Following shock, all mice remained in the chamber for 30 seconds
and were then immediately returned to their homecages. On the
following day, the mice were exposed to the same context and
behavior was recorded for three minutes.
Freezing was assessed as a measure of fear on all days using a 4
second sampling method by investigators, who were blind to the
genotype. The number of observed freezes was averaged and
divided by the total number of samples taken to yield a percentage
of freezing. Data is presented as the average percentage of freezing
during the three minutes test period.
Statistical Analysis
All statistical analysis was performed using the statistical
package SPSS v19 (Graduate pack) (SPSS Inc., Chicago, IL,
http://www.spss.com). Differences between means were assessed,
as appropriate, by one- or two- way ANOVA with or without
repeated measures, followed by Bonferroni post hoc analysis.
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Correlations were assessed by simple linear regression. For
behavioral studies, experiments were conducted three times for
correct statistical approach [33].
Results
Ab Expression and Plaque Formation Occurs in an Age-
Dependent Manner
An important characteristic of AD is the accumulation of the
protein Ab and the resulting formation of plaques throughout the
brain. To determine whether hAPP-J20 mice exhibit age-
dependent accumulation of cellular and extracellular Ab, we
measured total Ab using immunohistochemical techniques with
the 6E10 antibody in mice of different ages. We observed neuronal
Ab throughout the hippocampus at 6, 12, 24 and 36 weeks
(Figures 1A) Quantification of 6E10 immunoreactivity revealed a
significant increase in total Ab levels with age (Figure 1E;
F(3,24) = 23.14 p,0.001). A Bonferroni post-hoc analysis revealed a
significant increase in Ab at 12 (p,0.05), 24 (p,0.05) and 36
weeks (p,0.001) when compared to 6 weeks (Figure 1E).
Hippocampal oligomeric Ab expression also increased in an age-
dependent manner, and was significantly present by 36 weeks of
age (p,0.05; Figures 1C, 1D and 1G) and interestingly appeared
to form along the axons of neurons (Figure 1C). In addition to total
and oligomeric Ab, a significant number of plaques were present
at 36 weeks of age (p,0.001) (Figure 1B and 1F). This indicates
that the rise in hippocampal monomeric and oligomeric Ab
precedes plaque formation by a significant margin, as described in
other models of AD [34,35].
We further determined buffer-soluble hippocampal Ab in
hAPP-J20 mice at 6, 12, 24 and 36 weeks of age by a total Ab
sandwich ELISA. This showed a significant increase in total Ab
levels with age (Figure 1H; F(3,24) = 7.761 p,0.001). A Bonferroni
post-hoc analysis revealed a significant difference between 6
(p,0.001) and 12 weeks (p,0.05), when compared to 36 weeks
of age. Combined, these results demonstrate age-dependent
expression of Ab that is followed by senile plaque formation at
later stages in the hippocampus of hAPP-J20 mice.
hAPP-J20 Mice Exhibit Loss of Neurons in the CA1, but
not CA3, Region of the Hippocampus
Given the high abundance of Ab in the hippocampus of hAPP-
J20 mice starting at 6 weeks of age, and its association with cell loss
in other models [20,36], we hypothesized that Ab expression
would be associated with neurodegeneration in the hAPP-J20
mouse model. To examine whether hAPP-J20 also exhibits age-
dependent neuronal cell loss in the CA3 and CA1 regions of the
hippocampus, we performed unbiased stereological cell counts of
NeuN-labelled neurons under brightfield microscopy. Interesting-
ly, analysis of the neuronal population in the CA3 regions of the
hippocampus (Figure 2A) demonstrated no significant age-
dependent neuronal cell loss from 6, 12, 24 and 36 weeks of age
(interaction (F(7,29) = 0.783 p=0.514); age (F(7,29) = 0.645
p=0.593); genotype (F(7,29) = 2.107 p=0.158)).
However, we observed a significant genotype by age interaction
in the CA1 region of the hippocampus (F(7,29) = 5.264 p,0.01;
Figure 2B), thus suggesting age-dependent progressive loss of
neurons. Therefore, separate one-way ANOVAs were conducted
on genotype and age. Six-week-old hAPP-J20 mice did not show
neuronal cell deficits in the CA1 as compared to their age-matched
WT littermates. However, in contrast, significant neuronal loss in
the CA1 was observed in 12 (F(1,8) = 6.930 p,0.05), 24
(F(1,8) = 6.966 p,0.05) and 36 week (F(1,8) = 33.537 p,0.001;
Figure 2C and 2D) old hAPP-J20 mice, when compared to their
age-matched WT controls. A one-way ANOVA of genotype
indicated significant cell loss in the CA1 of hAPP-J20 mice with
age (F(3,14) = 4.807 p=0.017). A Bonferroni post-hoc analysis
revealed a significant difference in neuronal cell population
between 6 week and 36-week-old hAPP-J20 mice (p,0.001).
Additionally, there was a significant correlation of neuronal cell
loss and total Ab expression (Table 1; p,0.01). This is consistent
with the idea that Ab may be playing a direct or indirect role in
cell death in the CA1 region of the hippocampus, or, in theory,
that cell death is playing a role in Ab accumulation.
hAPP-J20 Mice Exhibit an Increased Astrocyte
Population, Reaching Saturation at 24 Weeks
Gliosis is a hallmark of AD and is characterized by the presence
of activated astrocytes. Astrocyte activation results in morpholog-
ical changes, including the shortening and thickening of processes,
increased proliferation and the release of pro-inflammatory factors
[11]. To determine the number of glial cells in the hippocampus of
the hAPP-J20 mouse model, we performed stereological cell
counts in the CA3 and CA1 regions of the hippocampus for
astrocyte cells that express the typical marker, GFAP. Our results
show that at 36 weeks of age (Figure 3A), hAPP-J20 possessed
more gliotic astrocytes when compared to age-matched WT mice
(Figure 3B). There was a significant interaction effect of genotype
by age for the CA3 region (F(7,29) = 4.013 p=0.021; Figure 3C).
Therefore, the effect of genotype and age on glial populations in
the CA3 was analyzed separately using a one-way ANOVA.
Significant differences were apparent in hAPP-J20 mice that were
24 weeks (F(1,8) = 9.454 p,0.05) and 36 weeks old (F(1,8) = 61.728
p,0.001) as compared to age-matched WT controls. There was a
trend towards significance of age in the CA3 (F(1,14) = 3.197
p=0.06) indicating that increased gliotic astrocytes may be age-
dependent in hAPP-J20 mice.
Results were similar in the CA1 region of the hippocampus,
where there was a significant genotype by age interaction effect
(F(7,29) = 4.013 p=0.021; Figure 3D). A one-way ANOVA of
genotypes revealed significant differences in the number of gliotic
astrocytes at 12 (F(1,8) = 7.862 p,0.05) and 24 weeks of age
(F(1,8) = 15.478 p,0.01), though interestingly not at 36 weeks of
age. There was an overall significant age effect on the number of
gliotic astrocytes in the CA1 region of the hippocampus of hAPP-
J20 mice (F(3,14) = 5.722 p,0.05). A Bonferroni post-hoc analysis
revealed a significant difference between 6 weeks and 24 weeks of
age (p,0.05). In addition, astrocyte numbers in the CA1 region
correlated significantly with total Ab levels (Table 1; p,0.05).
Combined, these results indicate that increases in reactive
astrocyte numbers in the hAPP-J20 mouse model is progressive
with age, though peaks at 24 weeks of age.
Microglial Activation Precedes Amyloid Plaque
Deposition
Microglial activation has been studied extensively in both mouse
models and patients of AD [16]. Microglial activation is
characterized by morphological changes from ramified (quiescent)
morphology to amoeboid (activated) morphology, the release of
pro-inflammatory cytokines and increased microglial cell number.
In addition, activated microglia express the marker CD68. As an
indicator of increased inflammation we analyzed brain tissue from
hAPP-J20 mice for changes in the number of CD68-positive
activated microglial cells in the area of the hippocampus bordered
by the CA1, CA3 and DG regions of the hippocampus. CD68-
positive microglia can be observed in clusters in the hAPP-J20
Inflammation and Cell Loss in a Mouse Model of AD
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(Figure 4B) when compared to WT (Figure 4A) mice at 36 weeks
of age.
Unbiased stereology was adopted to count CD68 positive
microglia. A two-way ANOVA of genotype and age revealed an
interaction effect (F(7,29) = 5.264 p,0.05) on the number of
activated microglia in the hippocampus. Therefore, one-way
ANOVAs were performed separately on genotype and age. A one-
way ANOVA of genotypes revealed significant differences at 24
(F(1,8) = 25.298 p,0.01) and 36 weeks of age (F(1,8) = 23.425
p,0.01), but not at 6 and 12 weeks of age when compared to
age-matched WT littermates. There was an overall significant age
effect (F(3,11) = 6.470 p,0.01). A Bonferroni post-hoc analysis
revealed a significant difference between 6 weeks and 36 weeks
of age (p,0.01). This indicates that activated microglia increase
with age in the hAPP-J20 mouse models of AD.
As found with reactive astrocytes, microglia cell populations
correlated with the expression of total Ab (Table 1; p,0.05). In
addition, microglia cell populations inversely correlated with the
number of neurons in the CA1 region of the hippocampus
(p,0.05). This shows that activated microglia populations are
closely associated with Ab expression and neuronal cell loss.
Figure 1. Age-dependent Ab expression and plaque deposition in the hAPP-J20 mice. (A) 6E10 immunohistochemistry illustrated
increased neuronal Ab from 6 to 12, 24 and 36-week-old hAPP-J20 mice (quantified in E). (B) Ab oligomer formation was not apparent until 24 weeks
of age and appeared by 36 weeks of age when it appeared to be associated with neuronal processes. (C) Plaques were present by 36 weeks of age,
but not earlier (quantified in F). (D and G) A dot plot quantification with the Ab-oligomer specific antibody, A11, revealed increases in Ab oligomers
through aging in the hAPP-J20 mouse, with a significant increase in 36-week-old hAPP-J20 mice. (H) Quantification of Ab by ELISA revealed an
increase in total Ab from 6 (p,0.05) and 12 (p,0.05) to 36 weeks of age in the hAPP-J20 mouse. Each value represents the mean6 standard error of
the mean (SEM). *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0059586.g001
Figure 2. Quantification of hippocampal neuronal populations in hAPP-J20 mice. (A) No cell loss was detected in the CA3 region of the
hippocampus of hAPP-J20 mice at 6, 24 and 36 weeks of age. (B) No cell loss in the CA1 region was detected at 6 weeks, however, 12 (p,0.05), 24
(p,0.05) and 36-week-old (p,0.001) mice showed significant cell loss when compared to aged-matched WT controls. Moreover, cell loss was
significantly different between 6 and 36-week-old hAPP-J20 mice (p,0.001). Cell loss in the CA1 region can be qualitatively seen between (C) WT and
(D) 36-week-old hAPP-J20 mice. Each value represents the mean 6 standard error of the mean (SEM). *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0059586.g002
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hAPP-J20 Mice Exhibit Hyperactivity, but no Differences
in Anxiety
In addition to anatomical changes, AD patients and mouse
models of AD exhibit profound behavioral alterations [37,38]. We
tested behavioral changes in the hAPP-J20 mouse model using the
elevated plus maze and open field test. The elevated plus maze and
open field tests are often used as a measure of anxiety and motor
activity, respectively. Several studies have indicated that hAPP-J20
mice have increased motor activity and spend more time in the
open arm of the elevated plus maze than WT controls, indicating
hyperactivity and lower levels of anxiety [28,39,40,41,42]. In
contrast, we found that although the hAPP-J20 mice tend to spend
more time in the open arms than the WT controls at 16
(F(1,21) = 1.97, p=0.176) and 24 weeks of age (F(1,12) = 6.024,
p=0.073), it is not significant (Figures 5A and 5B). However, as
shown in Figures 5C and 5D, locomotor activity in hAPP-J20 was
significantly increased at 16 weeks (F(1,21) = 13.91, p,0.001) and
Table 1. Correlations between CA1 regions (NeuN and GFAP),
CD68 cell numbers and total hippocampal Ab.
NeuN GFAP CD68
Ab r=0.77** r = 0.57* r = 0.66*
CD68 r = 0.80** r = 0.42
GFAP r=0.38
*p,0.05.
**p,0.01.
doi:10.1371/journal.pone.0059586.t001
Figure 3. Quantification of GFAP-positive astrocytes in hAPP-J20 mice. GFAP-positive astrocytes in the hippocampus were observed more
often in (B) 36-week-old hAPP-J20 mice compared to age-matched (A) WT littermates. (C) Quantification analysis revealed no differences in GFAP-
positive astrocytes in the CA3 at 6 or 12 weeks, however significant increases in cell number were detected at 24 (p,0.05) and 36 weeks (p,0.05). (D)
In the CA1 region of the hippocampus, there was no increase in GFAP-positive astrocytes at 6 and 36 weeks, though significant increases at 12
(p,0.05) and 24 weeks (p,0.05) were observed when compared to WT controls. In addition, a significant increase occurred between 6 week and 24-
week-old hAPP-J20 mice (p,0.05). Each value represents the mean 6 standard error of the mean (SEM). *p,0.05.
doi:10.1371/journal.pone.0059586.g003
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24 weeks of age (F(1,12) = 6.024, p,0.05) compared to WT
controls. Combined, these results indicate that hAPP-J20 mice
exhibit significantly increased levels of locomotor activity and no
changes in anxiety during later stages of AD progression.
hAPP-J20 Mice Show Spatial Reference Memory Deficits
at 16 and 24 Weeks of Age
AD is an amnesic disorder and is often associated with profound
memory loss [38]. It has been shown that in hAPP-J20 mice,
deficits in spatial memory and learning appear as the mice age
[39,43,44,45]. A powerful tool for measuring spatial memory and
learning is the RAM. Within the RAM, mice use spatial cues to
find the hidden food reward (Figure 6A). By using a reference
memory version of the RAM, we determined whether hAPP-J20
mice exhibit spatial memory and learning deficits at 16 (Figure 6B–
C) and 24 weeks of age (Figure 6D–E). An ANOVA with repeated
measures of 16-week-old hAPP-J20 mice and WT mice revealed a
significant genotype effect, trial, and a genotype by trial interaction
in reference memory (p,0.05; Figure 6B). These results indicate
that 16-week-old hAPP-J20 mice demonstrate spatial reference
memory deficits. As expected, we observed similar deficits in
spatial reference memory in 24-week-old hAPP-J20 mice (p,0.05;
Figure 6D).
Following a 14-day rest period, a retention test was performed.
Deficits in retention were detected in both 16 (Figure 6C;
F(1,11) = 8.22, p,0.05) and 24 weeks of age (Figure 6E;
F(1,16) = 4.65, p,0.05) hAPP-J20 mice as compared to age-
matched WT controls. These results demonstrate that hAPP-J20
mice exhibit long-term spatial memory and learning deficits.
hAPP-J20 Mice do not Show a Deficit in Contextual Fear
Conditioning
There is a vast amount of evidence to show contextual
memories are hippocampal-dependent [46]. As such, contextual
fear conditioning offers a valuable tool to assess both short-term
and long-term memory. Fear conditioning deficits have been
Figure 4. Quantification of CD68-positive activated microglia in hAPP-J20 mice. CD68-positive microglia were observed in the
hippocampus of (A) WT mice compared to (B) their hAPP-J20 littermates at 36 weeks of age. Quantification of CD68-positive cell numbers revealed
significant increases in cell numbers at 24 (p,0.01) and 36 weeks of age (p,0.01) in hAPP-J20 mice compared to their age-matched WT littermates.
Further, a significant increase in CD68 microglia occurred between 6 week and 36-week-old hAPP-J20 mice (p,0.01). Each value represents the mean
6 standard error of the mean (SEM). **p,0.01.
doi:10.1371/journal.pone.0059586.g004
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detected in other mouse models of AD [47,48], though not in the
hAPP-J20 mouse line [43]. Since we detected neurodegeneration
and deficits in spatial learning, we hypothesized contextual fear
memory and learning may also be impaired in the hAPP-J20
mouse model of AD. Figure 7A shows there is no difference in
freezing behavior at 28 weeks of age (F(1,15) =1.308, p=0.7321) as
compared to age-matched WT mice. In addition, mice assessed at
the 36 weeks of age also did not show a difference in freezing
behavior (F(1,27) = 0.433, p=0.511) as compared to age-matched
WT mice. In order to determine if long-term memory was
impaired in these mice, a retention test was performed on 36-
week-old mice, 28 days after their original training in the
paradigm. Somewhat surprisingly,at 40 weeks of age, no
differences occurred in the long-term retention test
(F(1,27) =0.140, p=0.711; Figure 7B).
Discussion
It has recently been suggested that successful treatment of AD
may require early intervention. This requires early diagnosis,
which in turn depends on identifying early pathological hallmarks
of disease. We therefore aimed to identify cellular correlates of
early AD in an APP overexpressing mouse, known as the hAPP-
Figure 5. hAPP-J20 mice exhibit hyperactivity. hAPP-J20 mice did not spend significantly more time in the open arm of the elevated plus maze
at (A) 16 or (B) 24 weeks of age indicating no difference in anxiety levels compared to age-matched WT littermates. However, hAPP-J20 mice did
show hyperactivity at (C) 16 and (D) 24 weeks of age as indicated by the total distance traveled in the open field test. Each value represents the mean
6 standard error of the mean (SEM). *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0059586.g005
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Figure 6. Spatial learning and memory deficits in hAPP-J20 mice. (A) Schematic representation of the radial arm maze. Filled circles represent
the baited arms (B) hAPP-J20 mice had significantly impaired spatial reference memory and learning at 16 weeks of age (p,0.05) when compared to
age-matched WT littermates. (C) 16-week-old hAPP-J20 mice had significant deficits in spatial reference memory and learning retention (p,0.05)
when compared to age-matched WT littermates. (D) 24-week-old hAPP-J20 mice also showed significantly impaired spatial reference memory and
learning (p,0.05) when compared to age-matched WT littermates. (E) Spatial reference memory and learning retention was significantly impaired in
24-week-old hAPP-J20 mice (p,0.05). Each value represents the mean 6 standard error of the mean (SEM). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0059586.g006
Inflammation and Cell Loss in a Mouse Model of AD
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e59586
J20 mouse model. These mice show plaque formation by seven
months of age but, interestingly, no tau hyperphosphorylation at
any of the major phosphorylation sites [24,28]. Our data indicates
that AD pathology including neuronal loss, inflammation and
behavioral impairment all occurs well before the formation of Ab
plaques, indicating that plaque load may not be the best early
diagnostic marker of AD. Therefore, other markers of disease may
need to be explored to track the progression of AD.
Neurodegeneration has been described in many mouse models
of AD [19,20,49,50] as well as AD patients [51]. However,
previous studies have suggested that neuronal loss does not occur
in the hAPP-J20 mouse line [52]. Our unbiased accurate estimate
of neuronal numbers in these mice revealed a progressive, age-
dependent neurodegeneration in the CA1 region, beginning at 12
weeks and reaching a 32% loss by 36 weeks (Figure 8).
Interestingly, cell loss does not occur in the CA3 region. This
selective loss of CA1 neurons parallels studies of human AD
patients that show greater neuron loss in the CA1 compared to the
CA3 region [53,54]. Though the exact reasons for this regional
difference are unknown, they may be due to differential expression
of both NMDA and AMPA receptor subunits, rendering the CA1
neurons more susceptible to excitotoxic cell death [55,56].
Although the precise mechanisms leading to neurodegeneration
in AD remain unclear, many studies indicate that Ab could play a
role in cell death by inducing mitochondrial oxidative stress and
other processes [35,57]. In this study, we have shown that there is
a correlation between cell death in the CA1 region of the
hippocampus and total Ab expression, suggesting that Ab may be
contributing directly or indirectly to cell death in this region.
Importantly, while neurodegeneration occurred in an age-depen-
dent manner, and correlated strongly with the expression of total
Ab, cell loss was observed at least 12 weeks before the onset of
plaques. Our data indicates that Ab is present as early as 6 weeks
of age and that this is most likely to be monomeric Ab. Oligomeric
Ab formation appears at 24 weeks of age, and is significantly
present by 36 weeks, forming along axons of neurons. Most
importantly, plaque formation did not occur significantly until 36
weeks of age, indicating that plaque load is not the major driver of
cell loss in this model of AD. While our study does not address
current questions regarding the role of Ab40 and Ab42 [58,59], it
does suggest that plaque load need not be the major contributor to
neurodegeneration, which begins at 12 weeks of age.
Inflammation is implicated in the etiology of AD. Many studies
indicate that the release of pro-inflammatory cytokines from
microglia and astrocytes can cause direct cell death of neurons
both in vivo and in vitro [60,61].We have shown, through quanti-
tative analysis, that the numbers of CD68-positive microglia was
significantly increased early in the hAPP-J20 mouse model. Our
data also shows that accumulation of microglia correlates with cell
death in the CA1 region of the hippocampus. Microglial
accumulation around plaques has been extensively described in
both AD patients and transgenic mouse models of AD and this is
associated with elevation in cytokine levels. Our quantitative
stereological analysis revealed significant increases in activated
(CD68-positive) microglia prior to Ab plaque deposition. In
addition, the change in CD68-positive microglia significantly
correlates with the extent of CA1 neuronal cell loss. Our data
raises the possibility that imaging microgliosis might offer an
approach to monitor AD progression in humans. Interestingly,
astrogliosis also begins in these mice, starting at 12 weeks of age,
though plateaus later in the disease progress. Other AD models
have shown age-dependent increases in astrogliosis, though it is
not clear why this phenomenon occurs in the hAPP-J20 model.
Nonetheless, our results are consistent with recent patient data,
which showed no correlation between microgliosis and astrogliosis
with plaque load [62].
The correlation between Ab and microglia, and microglia and
neuronal cell death in the CA1 region of the hippocampus,
supports the theory that monomeric and oligomeric Ab causes the
activation of microglia, which in turn is able to release pro-
inflammatory cytokines, stimulating toxic signaling pathways and
contributing to cell death [13,63,64]. Many pro-inflammatory
cytokines have been shown to directly contribute to neurodegen-
eration and, in parallel, molecules secreted from neurons can
promote further inflammatory processes [65]. This order of events
is consistent with the literature on the pro-inflammatory cytokines
Figure 7. Contextual fear conditioning is not impaired in hAPP-J20 mice. (A) No deficits were seen in the percentage of freezing in 28 and
36-week-old hAPP-J20 mice when compared to age-matched WT littermates. (B) A retention test, performed at 40 weeks, also revealed no deficits in
the percentage of freezing in 36-week-old hAPP-J20 mice when compared to age-matched controls. Each value represents the mean 6 standard
error of the mean (SEM).
doi:10.1371/journal.pone.0059586.g007
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that these cells secrete controlling the promoter activity of the APP
gene [66], thus upregulating production of APP generation in
many tissues, including brain [67,68,69,70,71,72,73]. Thus, as
these processes are occurring prior to plaque onset in the hAPP-
J20 mouse model, it is possible that neurodegeneration could be
occurring due to a cycle of inflammation and neurodegeneration
that further promotes inflammation. In this model activation of
inflammatory cells, either by Ab or by other mechanisms is a key
initiating event in AD that leads to a cycle of neurodegeneration
and further inflammation [13,74,75,76].
Behavioral impairments are a major constituent of AD and are
readily described in mouse models of AD. Previous studies have
characterized the hAPP-J20 mouse model using the Morris Water
Maze (MWM) [39,44,45,77], however interpretation has been
confounded by variable results in the cued version of the MWM
[28,78]. Therefore, in this study, spatial memory and learning was
investigated using the RAM. The RAM provides an advantage
over the MWM as the hAPP-J20 mouse model has a high
tendency to float and trend for thigmotactic swimming [43,45]. In
addition, the MWM can result in physical fatigue and hypother-
mia, which does not occur in the RAM. Furthermore, the RAM
takes advantage of the animals’ natural food exploratory behavior.
Our analysis of learning and memory by RAM revealed that the
hAPP-J20 mice display decreased learning and memory in a
hippocampal-dependent spatial memory task. Specifically, we
have revealed that spatial reference memory deficits occur in the
RAM at 16 and 24 weeks of age in the hAPP-J20 mouse model.
Moreover, we also found impairments in long-term memory
occurred 14 days following the RAM training. Therefore, memory
impairments occurred during the period that cell loss and
neuroinflammation occurs, but well before the onset of plaques.
These learning deficits seen in our study could not be due to
increased motor activity, since hyperactivity would correspond to a
decrease in the percentage of arms correct from the first session. As
the percentage of correct arms was the same for both hAPP-J20
and WT at 16 and 24-weeks of age, this indicates that there is no
correlation between hyperactivity and movement within the
RAM. Importantly, vision is not affected in the hAPP-J20 model
[79].
We also tested hAPP-J20 mice in a context fear-conditioning
paradigm to assess short- and long-term hippocampal-dependent
contextual memory. We found no deficits in contextual fear
conditioning at 28 weeks and 36 weeks of age. In addition, no
long-term contextual fear memory and learning deficits were
detected in the fear-conditioning paradigm. The results are
consistent with a recent study, which indicated spatial deficits
but no deficits in fear conditioning in the hAPP-J20 model [43]. It
is possible that compensatory mechanisms and/or alterations to
functionality of the fear circuit may account for the lack of deficit,
even in the absence of full hippocampal function [80,81].
There has been significant debate about the best approach for
tracking AD progression via PET [6]. Since our quantitative
stereological approach shows that CD68 positive cell numbers
correlate closely with loss of neuronal cell numbers and with Ab
expression, it is conceivable that a label of activated microglia may
potentially aid as a marker to track progression of AD. Therefore
our work raises a question as to whether PET imaging of a marker
of activated microglia, while not diagnostic, might offer a useful
way to track disease progression. Activated microglia can be
detected in vivo using PET scan imaging, with the selective
radioligand known as 11C-PK11195, which is known to correlate
with levels of CD68-positive microglia [82]. Indeed, PET scanning
in a small cohort of patients with mild cognitive impairments
(MCI) has revealed the presence of activated microglia [83]. 11C-
PK11195 labelling is significantly increased in AD patients
[84,85,86] and animal models [82]. In addition 11C-PK11195-
labelled activated microglia has been shown to correlate with AD
patient Mini-Mental State examination scores [85]. Since MCI
has been shown to be a precursor for early AD there is therefore a
considerable need to further investigate microglial markers, such
as CD68, for PET scanning in a larger sample size of very early
Figure 8. Time course of disease progression, as a percentage of hAPP-J20 6-week-old mice. Mice exhibit 32% loss of neurons in the CA1
region of the hippocampus between 6 weeks and 36 weeks of age. In addition, a 163% increase in the number of CD68-positive microglia and a 62%
increase in the number of CA1 GFAP-positive astrocytes occurred between 6 weeks and 36 weeks of age. Total Ab expression increases by 242%
between the ages of 6 weeks and 36 weeks of age. Small arrow represents plaque load in some mice, while larger arrow represents plaque load in all
mice.
doi:10.1371/journal.pone.0059586.g008
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AD patients. CD68-positive microglia, combined with other
markers, may be ultimately utilized to track AD progression.
The consistent conclusion of our study, taken together with
other studies [20,34,87,88], is that behavioral decline, neuronal
cell death and inflammatory cell activation precede plaque
deposition, providing a strong indication that neurodegenerative
processes are occurring independent of Ab protein. Fundamentally
this means that AD progressive decline may occur well before
plaque deposition in patients. At present, the Ab protein is often
regarded as a central component to brain degradation in AD. As
such, imaging studies and therapeutic targets [29,89,90] are
largely based around decreasing Ab deposition in the brain; and
new techniques such as MRI and PET scanning for Ab can only
detect fibrillar forms, and are mostly directed at imaging plaques
[29,30]. In this study, we show that other hallmarks of AD, such as
neuronal loss, neuroinflammation and behavioral deficits are
vastly progressed before plaque onset in a mouse model of AD.
Our study shows a correlation between activated microglia, Ab
and neuronal cell loss, but not Ab deposition in plaques,
highlighting the potential importance that microglia may play in
the early development of degeneration and cognitive decline in
AD. Therefore the imaging of microglia using PET could be a
useful indicator for the progression and early detection of AD.
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